Updates are available Correction dated 2024-09-10

Article History

Received: 8 April 2024

Accepted: 14 August 2024

First Online: 2 September 2024

Change Date: 10 September 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1186/s13046-024-03183-9

Declarations

:

: All experimental procedures involving animals were conducted strictly with the guidelines and regulations established by UT MD Anderson's Institutional Animal Care and Use Committee.

: Not applicable.

: JWW reports research support from Bristol Meyers Squibb, Alkermes, Genentech, Nanobiotix, Artidis, Merck, Takeda, Varian, Astra Zeneca, HotSpot Therapeutics, Inc., Gilead, Kiromic, Sciclone, Pebble, Novocure and Bayer Healthcare. JWW serves/served on the scientific advisory board/Consultant for Accuray, Alkermes, Alpine Immune Science, Astra Zeneca, Boehringer Ingelheim, Checkmate Pharmaceuticals, China Medical Tribune, Genentech, GI Innovation, Kezar Life Science, Legion Healthcare Partners, Life Science Dynamic Limited, McKesson Corporation, Nanobiotix, Nanorobotics, Novocure, OncoResponse, RefleXion Medical, Roche, Roche Molecular Systems, Taiwan Lung Cancer Society, The Radiosurgery Society. JWW holds/held stock or ownership in Alpine Immune Sciences, Checkmate Pharmaceuticals, MolecularMatch, OligoImmune, RefleXion, OncoResponse, Welsh DV8. JWW has accepted honoraria in the form of travel costs from Nanobiotix, RefleXion, Varian. JWW has the following patents: MP470 (amuvatinib), MRX34 regulation of PDL1, XRT technique to overcome immune resistance. MD Anderson Cancer Center has a trademark for RadScopal™. HBB and NPO serve as part-time consultants for Research Guided Cancer Treatment Consults LLC. The rest of the authors disclosed no competing interests.